JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1988; 12:175-186
© 1988 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molina, C.
Right arrow Articles by Murad, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molina, C.
Right arrow Articles by Murad, F

Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure

CR Molina, MB Fowler, S McCrory, C Peterson, BD Myers, JS Schroeder, and F Murad

Division of Cardiology, Stanford University Medical Center, California 94305.

The cardiac release and total body and renal clearances and the hemodynamic, renal and endocrine effects of increasing doses of atrial natriuretic peptide were investigated in 12 patients with severe chronic congestive heart failure. Immunoreactive arterial plasma levels of atrial natriuretic peptide were 10-fold higher than normal and there was no correlation between aortic atrial natriuretic peptide and cardiac filling pressures. The heart released atrial natriuretic peptide into the coronary sinus. The kidney, though a major clearance site, accounted for only 33% of the total body clearance. Administration of 0.3 micrograms/kg per min atrial natriuretic peptide produced significant changes in heart rate (95 +/- 4 to 85 +/- 4 beats/min) and mean arterial (92 +/- 8 to 77 +/- 9 mm Hg), right atrial (13 +/- 3 to 8 +/- 2 mm Hg) and mean pulmonary artery occluded (27 +/- 3 to 14 +/- 3 mm Hg) pressures. Atrial natriuretic peptide increased cardiac index (2.25 +/- 0.18 to 2.83 +/- 0.3 liters/min per m2) and stroke work index (21 +/- 1.5 to 29 +/- 3.4 g/m2), whereas systemic vascular resistance (1,424 +/- 139 to 1,033 +/- 97 dynes.s.cm(-5)) decreased. Infusion of 0.1 microgram/kg per min atrial natriuretic peptide increased urinary flow 128%, fractional excretion of sodium 133% and fractional excretion of potassium 35%. The filtration fraction increased from 29 +/- 2 to 31 +/- 4%. This represented a disproportionate rise in glomerular filtration rate over renal plasma flow. Plasma aldosterone and norepinephrine decreased whereas plasma renin activity remained unchanged. In association with these hemodynamic, excretory and endocrine changes, the urinary excretion of cyclic guanosine monophosphate doubled. Placebo had no effect. These results showed that, despite high circulating levels of atrial natriuretic peptide, administration of this hormone in heart failure is associated with potentially beneficial hemodynamic, renal and endocrine effects.


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
R. M. Witteles, D. Kao, D. Christopherson, K. Matsuda, R. H. Vagelos, D. Schreiber, and M. B. Fowler
Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1835 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
O. Celik, I. Sahin, N. Celik, S. Hascalik, L. Keskin, H. Ozcan, A. Uckan, and F. Kosar
Diagnostic potential of serum N-terminal pro-B-type brain natriuretic peptide level in detection of cardiac wall stress in women with polycystic ovary syndrome: a cross-sectional comparison study
Hum. Reprod., November 1, 2007; 22(11): 2992 - 2998.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Schmitt, P. Gunaruwan, N. Payne, J. Taylor, L. Lee, A. J.M. Broadley, A. K. Nightingale, J. R. Cockcroft, A. D. Struthers, J. V. Tyberg, et al.
Effects of Exogenous and Endogenous Natriuretic Peptides on Forearm Vascular Function in Chronic Heart Failure
Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 911 - 917.
[Abstract] [Full Text]

Home page
 PediatricsHome page
T. S. Mir, R. Laux, H. H. Hellwege, B. Liedke, C. Heinze, H. von Buelow, S. Laer, and J. Weil
Plasma Concentrations of Aminoterminal Pro Atrial Natriuretic Peptide and Aminoterminal Pro Brain Natriuretic Peptide in Healthy Neonates: Marked and Rapid Increase After Birth
Pediatrics, October 1, 2003; 112(4): 896 - 899.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. R. McClean, H. Ikram, S. Mehta, J. T. Heywood, M. F. Rousseau, A. L. Niederman, R. F. Sequeira, E. Fleck, S. N. Singh, B. Coutu, et al.
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects
J. Am. Coll. Cardiol., June 19, 2002; 39(12): 2034 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. A. Sagnella
Atrial natriuretic peptide mimetics and vasopeptidase inhibitors
Cardiovasc Res, August 15, 2001; 51(3): 416 - 428.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch
Therapeutic benefits of increasing natriuretic peptide levels
Cardiovasc Res, August 15, 2001; 51(3): 510 - 520.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. R. McClean, H. Ikram, A. H. Garlick, A. M. Richards, M. G. Nicholls, and I. G. Crozier
The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure
J. Am. Coll. Cardiol., August 1, 2000; 36(2): 479 - 486.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Matsumoto, A. Wada, T. Tsutamoto, T. Omura, H. Yokohama, M. Ohnishi, I. Nakae, M. Takahashi, and M. Kinoshita
Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure
Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1935 - H1942.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. L. Abramson, S.-i. Ando, C. F. Notarius, G. A. Rongen, and J. S. Floras
Effect of Atrial Natriuretic Peptide on Muscle Sympathetic Activity and Its Reflex Control in Human Heart Failure
Circulation, April 13, 1999; 99(14): 1810 - 1815.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. S. Marcus, D. Hart, M. Packer, M. Yushak, N. Medina, R. S. Danziger, D. F. Heitjan, and S. D. Katz
Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Crossover Trial
Circulation, December 15, 1996; 94(12): 3184 - 3189.
[Abstract] [Full Text]

Home page
 CirculationHome page
R. O. Bonow
New Insights Into the Cardiac Natriuretic Peptides
Circulation, June 1, 1996; 93(11): 1946 - 1950.
[Full Text]

Home page
 CirculationHome page
G. Iervasi, A. Clerico, S. Berti, A. Pilo, A. Biagini, R. Bianchi, and L. Donato
Altered Tissue Degradation and Distribution of Atrial Natriuretic Peptide in Patients With Idiopathic Dilated Cardiomyopathy and Its Relationship With Clinical Severity of the Disease and Sodium Handling
Circulation, April 1, 1995; 91(7): 2018 - 2027.
[Abstract] [Full Text]

Home page
 HypertensionHome page
J. G. Motwani, C. C. Lang, G. Cramb, and A. D. Struthers
Natriuretic Response to Neutral Endopeptidase Inhibition Is Blunted by Enalapril in Healthy Men
Hypertension, April 1, 1995; 25(4): 637 - 642.
[Abstract] [Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1988 by the American College of Cardiology Foundation.